|
| | Halofuginone hydrobromide Basic information |
| | Halofuginone hydrobromide Chemical Properties |
| Melting point | 247° (dec) | | storage temp. | Store at -20°C | | solubility | Soluble to 100 mM in DMSO. | | form | neat |
| Hazard Codes | Xn | | Risk Statements | 22 | | RIDADR | UN2811 - class 6.1 - PG 1 - EHS - Toxic solids, organic, n.o.s., HI: all | | WGK Germany | 3 | | RTECS | VA2397066 |
| | Halofuginone hydrobromide Usage And Synthesis |
| Description | Halofuginone hydrobromide (Halofuginone) is a specific collagen Type I inhibitor that antagonize or inhibit the development of new blood vessels, hence can prevent intimal hyperplasia at a vascular anastomosis. It is used in the treatment or prevention of coccidiosis in both humans and animals. | | Chemical Properties | White to Off-White Solid | | Uses | Halogenated derivative of Febrifugine. Halofuginone hydrobromide is used as an antiprotozoal (coccidiostat).
| | Definition | The hydrobromide salt of halofuginone, a semisynthetic quinazolinone alkaloid anticoccidial derived from the plant Dichroa febrifuga, with antifibrotic and potential antineoplastic activities. Halofuginone specifically inhibits collagen type I gene expression and matrix metalloproteinase 2 (MMP-2) gene expression, which may result in the suppression of angiogenesis, tumor stromal cell development, and tumor cell growth. These effects appear to be due to halofuginone-mediated inhibition of the collagen type I and MMP-2 promoters. Collagen type I and MMP-2 play important roles in fibro-proliferative diseases. | | Biological Activity | Halofuginone hydrobromide is a high affinity competitive prolyl-tRNA synthetase inhibitor (Ki = 18.3 nM). Blocks expression of MMP2. Inhibits ECM invasion in vitro and lung metastasis by bladder cancer cells in mice. Inhibits the development of Th17-driven autoimmunity in a mouse model of multiple sclerosis by activating the amino acid response (AAR) pathway. Also antiparasitic. | | storage | Store at -20°C | | Mode of action | Halofuginone is an an ATP-dependent inhibitor prolyl-tRNA synthetase (Ki of 18.3 nM). Halofuginone attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Blocks expression of MMP2 and inhibits ECM invasion in vitro and lung metastasis by bladder cancer cells in mice. Also inhibits the development of Th17-driven autoimmunity in a mouse model of multiple sclerosis by activating the amino acid response (AAR) pathway. |
| | Halofuginone hydrobromide Preparation Products And Raw materials |
|